Cargando…
Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19
Vinpocetine (VPN) is an alkaloid derivative of vincamine inhibits phosphodiesterase type 1 that increase cyclic guanosine monophosphate and cyclic adenosine monophosphate. VPN have anti-inflammatory and antioxidant effects with suppression release of pro-inflammatory cytokines. Moreover, VPN mitigat...
Autores principales: | Al-kuraishy, Hayder M, Al-Gareeb, Ali I, Fageyinbo, Muyiwa Samuel, Batiha, Gaber El-Saber |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017700/ https://www.ncbi.nlm.nih.gov/pubmed/35662743 http://dx.doi.org/10.2144/fsoa-2021-0099 |
Ejemplares similares
-
Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2018) -
Vinpocetine Improves Oxidative Stress and Pro-Inflammatory Mediators in Acute Kidney Injury
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2019) -
New insights on the potential effect of vinpocetine in Parkinson’s disease: one of the neglected warden and baffling topics
por: Al-kuraishy, Hayder M., et al.
Publicado: (2023) -
Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020) -
Potential role of lipoxin in the management of COVID-19: a narrative review
por: Batiha, Gaber El-Saber, et al.
Publicado: (2022)